Effect of Epstein-Barr Virus Infection on Connective Tissue Disease-associated Interstitial Pneumonia
Department of Respiratory and Critical Care Medicine,Guizhou Provincial People's Hospital/State Key Laboratory of Diagnosis and Treatment of Lung Immune Diseases,Guiyang 550002,China
*Corresponding author:ZHANG Yiling,Associate professor,Associate chief physician;E-mail:yilingzhang@126.com
[1]YUI S,YAMAGUCHI H,IMADOME K,et al.Epstein-Barr virus-positive T-cell lymphoproliferative disease following umbilical cord blood transplantation for acute myeloid leukemia[J].Nippon Ika Daigaku Zasshi,2016,83(1):35-42.DOI:10.1272/jnms.83.35.
[2]SUN L,HUANG M J,WANG J C,et al.Genotyping of pneumocystis jirovecii isolates from human immunodeficiency virus-negative patients in China[J].Infect Genet Evol,2015,31:209-215.DOI:10.1016/j.meegid.2015.01.021.
[3]KAWAMOTO K,MIYOSHI H,SUZUKI T,et al.A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder:adult patients with chronic active Epstein-Barr virus infection-like features[J].Haematologica,2018,103(6):1018-1028.DOI:10.3324/haematol.2017.174177.
[4]YAO J J,ZHOU G Q,WANG Y Q,et al.Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma[J].Chin J Cancer,2017,36(1):98.DOI:10.1186/s40880-017-0264-x.
[5]MATHAI S C,DANOFF S K.Management of interstitial lung disease associated with connective tissue disease[J].BMJ,2016,352:h6819.DOI:10.1136/bmj.h6819.
[6]CHUNG J H,COX C W,MONTNER S M,et al.CT features of the usual interstitial pneumonia pattern:differentiating connective tissue disease-associated interstitial lung disease from idiopathic pulmonary fibrosis[J].AJR Am J Roentgenol,2018,210(2):307-313.DOI:10.2214/AJR.17.18384.
[7]JIN Q,ZHENG J S,XU X R,et al.Value of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in evaluating severity and prognosis of connective tissue disease-associated interstitial lung disease[J].Arch Rheumatol,2018,33(2):190-197.DOI:10.5606/ArchRheumatol.2018.6419.
[8]YAMANO Y,TANIGUCHI H,KONDOH Y,et al.Multidimensional improvement in?connective tissue disease-associated interstitial lungdisease:two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus[J].Respirology,2018,23(11):1041-1048.DOI:10.1111/resp.13365.Epub 2018 Jul 16.
[9]SAUNDERS P,TSIPOURI V,KEIR G J,et al.Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease(RECITAL):study protocol for a randomised controlled trial[J].Trials,2017,18(1):275.DOI:10.1186/s13063-017-2016-2.
[10]YACHIE A.Cytologic analysis of Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative diseases[J].Front Pediatr,2018,6:327.DOI:10.3389/fped.2018.00327.
[11]FROST T C,GEWURZ B E.Epigenetic crossroads of the Epstein-Barr virus B-cell relationship[J].Curr Opin Virol,2018,32:15-23.DOI:10.1016/j.coviro.2018.08.012.
[12]SALLOUM N,HUSSEIN H M,JAMMAZ R,et al.Epstein-Barr virus DNA modulates regulatory T-cell programming in addition to enhancing interleukin-17A production via Toll-like receptor 9[J].PLoS One,2018,13(7):e0200546.DOI:10.1371/journal.pone.0200546.
[13]SAMSUDIN I,VASIKARAN S D.Clinical utility and measurement of procalcitonin[J].Clin Biochem Rev,2017,38(2):59-68.
[14]LIPPI G,SANCHIS-GOMAR F.Procalcitonin in inflammatory bowel disease:drawbacks and opportunities[J].World J Gastroenterol,2017,23(47):8283-8290.DOI:10.3748/wjg.v23.i47.8283.
[15]VIJAYAN A L,VANIMAYA,RAVINDRAN S,et al.Procalcitonin:a promising diagnostic marker for Sepsis and antibiotic therapy[J].J Intensive Care,2017,5:51.DOI:10.1186/s40560-017-0246-8.
[16]SALVO P,DINI V,KIRCHHAIN A,et al.Sensors and biosensors for C-reactive protein,temperature and pH,and their applications for monitoring wound healing:a review[J].Sensors(Basel),2017,17(12):332-339.DOI:10.3390/s17122952.
[17]SMITH K J,AU B,OLLIS L,et al.The association between C-reactive protein,Interleukin-6 and depression among older adults in the community:a systematic review and meta-analysis[J].Exp Gerontol,2018,102:109-132.DOI:10.1016/j.exger.2017.12.005.
[18]IWAKIRI Y,KIM M Y.Nitric oxide in liver diseases[J].Trends Pharmacol Sci,2015,36(8):524-536.DOI:10.1016/j.tips.2015.05.001.
[19]HE X F,LI W,ZHU L M,et al.Investigation for effects of iNOS on biological function of chondrocytes in rats with post-traumatic osteoarthritis[J].Eur Rev Med Pharmacol Sci,2018,22(21):7140-7147.DOI:10.26355/eurrev_201811_16245.
[20]EKMEKCIOGLU S,GRIMM E A,ROSZIK J.Targeting iNOS to increase efficacy of immunotherapies[J].Hum Vaccin Immunother,2017,13(5):1105-1108.DOI:10.1080/21645515.2016.1276682.
[21]ROSE-JOHN S,WINTHROP K,CALABRESE L.The role of IL-6 in host defence against infections:immunobiology and clinical implications[J].Nat Rev Rheumatol,2017,13(7):399-409.DOI:10.1038/nrrheum.2017.83.
[22]MA L,ZHANG H,YIN Y L,et al.Role of interleukin-6 to differentiate Sepsis from non-infectious systemic inflammatory response syndrome[J].Cytokine,2016,88:126-135.DOI:10.1016/j.cyto.2016.08.033.
[23]NANKE Y,YAGO T,KOTAKE S.The role of Th17 cells in the pathogenesis of behcet's disease[J].J Clin Med,2017,6(7):74.DOI:10.3390/jcm6070074.
[24]ISAILOVIC N,DAIGO K,MANTOVANI A,et al.Interleukin-17 and innate immunity in infections and chronic inflammation[J].J Autoimmun,2015,60:1-11.DOI:10.1016/j.jaut.2015.04.006.
[25]PATIL R S,BHAT S A,DAR A A,et al.The jekyll and hyde story of IL17-producing γδT cells[J].Front Immunol,2015,6:37.DOI:10.3389/fimmu.2015.00037.
[26]SHEN J X,LIU J,ZHANG G J.Interleukin-33 in malignancies:friends or foes?[J].Front Immunol,2018,9:3051.DOI:10.3389/fimmu.2018.03051.
[27]FAIRLIE-CLARKE K,BARBOUR M,WILSON C,et al.Expression and function of IL-33/ST2 axis in the central nervous system under normal and diseased conditions[J].Front Immunol,2018,9:2596.DOI:10.3389/fimmu.2018.02596.
[28]LI L Y,ZHU H L,ZUO X.Interleukin-33 in systemic sclerosis:expression and pathogenesis[J].Front Immunol,2018,9:2663.DOI:10.3389/fimmu.2018.02663.
[29]CAO P F,ZHANG M L,WANG L J,et al.MiR-18a reactivates the Epstein-Barr virus through defective DNA damage response and promotes genomic instability in EBV-associated lymphomas[J].BMC Cancer,2018,18(1):1293.DOI:10.1186/s12885-018-5205-9.
[30]GUAN Y,JAKIMOVSKI D,RAMANATHAN M,et al.The role of Epstein-Barr virus in multiple sclerosis:from molecular pathophysiology to in vivo imaging[J].Neural Regen Res,2019,14(3):373-386.DOI:10.4103/1673-5374.245462.
[31]VISTAROP A G,COHEN M,HUAMAN F,et al.The interplay between local immune response and Epstein-Barr virus-infected tonsillar cells could lead to viral infection control[J].Med Microbiol Immunol,2018,207(5/6):319-327.DOI:10.1007/s00430-018-0553-2.
[32]HANADA S,PIRZADEH M,CARVER K Y,et al.Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia[J].Front Immunol,2018,9:2640.DOI:10.3389/fimmu.2018.02640.
[33]MORGAN D J,CASULLI J,CHEW C,et al.Innate immune cell suppression and the link with secondary lung bacterial pneumonia[J].Front Immunol,2018,9:2943.DOI:10.3389/fimmu.2018.02943.